'Deep dive' into biology of kidney tumors identifies markers of response to immunotherapy
Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year. ...
Sep 8, 2020
0
33